AKT1 and neoplasm: We show that CDK4/6 inhibitor resistance following long-term exposure to palbociclib has the potential to upregulate PI3K-AKT signalling, downregulate ER pathways, and influence subsequent effects of both AKT and ER inhibition on tumour cell signalling and function.